Atlas Trials

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

Clinical trial NCT02831764 · COMPLETED

Trial details

NCT number
NCT02831764
Sponsor
ViiV Healthcare
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Infection, Human Immunodeficiency VirusHIV Infections
Start date
2016-07-18
Primary completion
2018-04-04
Enrollment
722

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.